Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Exploring Praxis Precision Medicines’ elsunersen for Early-Onset SCN2A Developmental and Epileptic Encephalopathies

Ticker(s): PRAX, PFE, GSK, NVS, ABBV, JNJ, ESALF

Who's the expert?

Institution: Mayo Clinic

Director of Pediatric Epilepsy at the Mayo Clinic & Co-founder of the Pediatric Epilepsy Research Consortium.
Clinical focus includes Early-onset epilepsies and epileptic encephalopathies, including West syndrome, Dravet syndrome, myoclonic atonic epilepsy of Doose, Lennox-Gastaut syndrome and CSW, Medically intractable pediatric epilepsy, Ketogenic diet therapy, and Surgical therapy for epilepsy.
Currently manages 10 adults with focal epilepsy and follows ~750 pediatric patients with Refractory Epilepsy.

Interview Goal

On this call, we aim to assess the clinical relevance and potential adoption of elsunersen based on EMBRAVE study findings, including its impact on seizure reduction, unmet need in SCN2A-DEE, differentiation from current treatments, and implications for future regulatory and commercial success.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here To Join
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Call Date: Apr 14, 2026
Call Time: 07:45 AM EDT

Wall Street Time

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here To Join
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.